Bringing a new treatment option for patients with the fast-killing blood cancer multiple myeloma, Millennium Pharmaceuticals Inc. won FDA approval of the proteasome inhibitor Velcade (bortezomib) and plans to launch it next week. (BioWorld Today) Read More
